Molecules of Korolchuk IP-NFT
What is this project about? VitaDAO is a decentralized autonomous organization that launched VITA-FAST, an innovative financing model for longevity research. Using the Ethereum blockchain,VITA-FAST is ERC-20 tokens, representing fractional ownership of the non-fungible token (IP-NFT) for the intellectual property arising from longevity research conducted by the University of Newcastle's Korolchuk Laboratory.VITA-FAST Token holders gain governance rights over IP, thereby making decision-making in scientific research more democratic. 1. What is this project about? This project focuses on discovering and developing therapeutic compounds capable of reactivating autophagy in Npc1 -/- cells. This includes screening bioactive and commercially available small molecules in cell viability assays to identify potential autophagy activators that do not cause cytotoxicity. The project uses advanced techniques, including luciferase-p6 clearance and photo-GFP-LC3 orthogonal assays. 2. What makes your project unique? The uniqueness of this project lies in its approach to identifying novel compounds capable of inducing autophagy in NPC1-/- cells; autophagy is a key process for treating Niemann-Pick disease type C. Unlike existing therapeutic approaches, this project uses high-throughput screening methods and innovative assays to discover compounds with high chemical diversity and no similarity to existing autophagy inducers, opening up possibilities for new intellectual property. 3. Your project history. The project is led by Dr. Korolchuk and his team at the University of Newcastle. It has progressed from generating data on thousands of compounds using advanced screening assays to identifying lead compounds with potential autophagic properties. The project has advanced to include synthesizing derivatives of these compounds and is now moving toward the drug translation process, including pharmacokinetic and scalability studies. 4. What is the next step for your project? The next steps include screening third-generation compounds and conducting in vitro and in vivo model studies using patients
Overview
What is this project about? VitaDAO is a decentralized autonomous organization that launched VITA-FAST, an innovative financing model for longevity research. Using the Ethereum blockchain,VITA-FAST is ERC-20 tokens, representing fractional ownership of the non-fungible token (IP-NFT) for the intellectual property arising from longevity research conducted by the University of Newcastle's Korolchuk Laboratory.VITA-FAST Token holders gain governance rights over IP, thereby making decision-making in scientific research more democratic. 1. What is this project about? This project focuses on discovering and developing therapeutic compounds capable of reactivating autophagy in Npc1 -/- cells. This includes screening bioactive and commercially available small molecules in cell viability assays to identify potential autophagy activators that do not cause cytotoxicity. The project uses advanced techniques, including luciferase-p6 clearance and photo-GFP-LC3 orthogonal assays. 2. What makes your project unique? The uniqueness of this project lies in its approach to identifying novel compounds capable of inducing autophagy in NPC1-/- cells; autophagy is a key process for treating Niemann-Pick disease type C. Unlike existing therapeutic approaches, this project uses high-throughput screening methods and innovative assays to discover compounds with high chemical diversity and no similarity to existing autophagy inducers, opening up possibilities for new intellectual property. 3. Your project history. The project is led by Dr. Korolchuk and his team at the University of Newcastle. It has progressed from generating data on thousands of compounds using advanced screening assays to identifying lead compounds with potential autophagic properties. The project has advanced to include synthesizing derivatives of these compounds and is now moving toward the drug translation process, including pharmacokinetic and scalability studies. 4. What is the next step for your project? The next steps include screening third-generation compounds and conducting in vitro and in vivo model studies using patients